Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CorMedix (CRMD) Net Income towards Common Stockholders: 2012-2025

Historic Net Income towards Common Stockholders for CorMedix (CRMD) over the last 12 years, with Sep 2025 value amounting to $108.5 million.

  • CorMedix's Net Income towards Common Stockholders rose 4001.20% to $108.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.0 million, marking a year-over-year increase of 496.10%. This contributed to the annual value of -$17.9 million for FY2024, which is 62.52% up from last year.
  • As of Q3 2025, CorMedix's Net Income towards Common Stockholders stood at $108.5 million, which was up 434.36% from $20.3 million recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Net Income towards Common Stockholders peaked at $108.5 million during Q3 2025, and registered a low of -$14.5 million during Q1 2024.
  • For the 3-year period, CorMedix's Net Income towards Common Stockholders averaged around $10.0 million, with its median value being -$6.3 million (2023).
  • As far as peak fluctuations go, CorMedix's Net Income towards Common Stockholders slumped by 250.96% in 2023, and later surged by 4,001.20% in 2025.
  • Over the past 5 years, CorMedix's Net Income towards Common Stockholders (Quarterly) stood at -$7.8 million in 2021, then declined by 5.36% to -$8.2 million in 2022, then tumbled by 42.18% to -$9.7 million in 2023, then spiked by 71.45% to $13.5 million in 2024, then surged by 4,001.20% to $108.5 million in 2025.
  • Its last three reported values are $108.5 million in Q3 2025, $20.3 million for Q2 2025, and $20.6 million during Q1 2025.